The China Discount: Arbitraging Undervalued Chinese ADC & Bispecific Assets

The China Discount Thesis in One Paragraph

The China discount is the persistent gap between what a clinical-stage Chinese-originated asset costs to license and what a comparable Western asset commands. For most of the last decade, that gap was wide: dealmaking analyses put Chinese upfronts at roughly 60-70% below Western comparables and total deal sizes 40-50% lower. The thesis is that this gap reflects the value of the Chinese market for the asset — which is structurally compressed — rather than the scientific or clinical quality of the molecule itself, which is increasingly world-class. A Western buyer who can acquire global or ex-China rights at the discounted price and then develop and sell the drug in high-reimbursement Western markets captures the spread. That spread is the arbitrage, and in 2025 it drove roughly a third of all global out-licensing value to China. The rest of this analysis explains why the discount exists, how the trade is executed, where it has already closed, and what survives.

This article is the conceptual anchor for our China practice. For the live deal data behind it, see our China Out-Licensing Report 2026; for the broader market map, our China biotech ecosystem guide.

Why Chinese Assets Are Undervalued

The discount is not a market inefficiency in the lazy sense — it is the rational output of three real, compounding forces. A buyer who treats it as “free money” misunderstands it; a buyer who understands its sources can isolate the part of the discount that is genuine arbitrage from the part that is risk compensation.

1. Domestic price compression caps the home-market value

The most fundamental driver is that the Chinese market simply pays less for innovative drugs than the West. Two state mechanisms enforce this. The National Reimbursement Drug List (NRDL) requires drugmakers to accept steep price cuts in exchange for nationwide reimbursement coverage — the 2024 negotiation cycle produced an average price cut of about 63%, the steepest in recent years (BioWorld, Simon-Kucher). Separately, volume-based procurement (VBP) runs winner-takes-most tenders for off-patent and maturing products, driving average cuts of 50-54% and, in extreme cases, up to 96%. The mechanics and deal implications of both are detailed in our China asset pricing guide on NRDL and VBP. The consequence for valuation is direct: a molecule that might generate billions in the US earns a small fraction of that at home, so its China-rights value — and therefore the price an originator can defend if it keeps only the home market — is structurally low.

2. A capital and IPO drought forces early monetization

The second force is financing. Chinese biotech venture investment peaked in 2021 and then collapsed to about $4.2 billion in 2024 (Stifel) amid a broad market downturn (Wellington Management). The Hong Kong Exchange — the primary listing venue for pre-revenue Chinese biotechs under its Chapter 18A regime — went through a deep down-cycle, with mega-rounds drying up and valuations falling. With equity capital scarce and expensive, out-licensing became a critical alternative financing channel: a Chinese biotech can convert a clinical asset into hundreds of millions of non-dilutive dollars by selling ex-China rights. That financing pressure is a motivated seller dynamic — and motivated sellers accept lower prices than they would in a flush capital market.

3. A geopolitical and regulatory risk premium

The third force is the discount buyers apply for cross-border risk. The BIOSECURE Act, enacted in December 2025, created policy uncertainty around US engagement with Chinese biotech (even though, as enacted, it restricts federal procurement of services and equipment from to-be-designated “biotechnology companies of concern” rather than asset licensing). Layered on top is regulatory risk: the FDA’s 2022 rejection of sintilimab established that pivotal data generated solely in China may not be generalizable to US patients, meaning buyers often must fund additional multiregional trials. Rational buyers price these contingencies into the upfront, widening the discount.

How Western Pharma Arbitrages the Gap

The mechanics of the trade are simple to state and demanding to execute. A Western buyer acquires global or ex-China rights to a de-risked, clinical-stage Chinese asset at an upfront that looks low against Western comparables. The originator keeps the price-compressed home market — the part it can defend and the part the West does not want — while the buyer takes the high-reimbursement territories: the United States, Europe, and Japan. The buyer then runs the asset through Western development and commercialization, where the same molecule can earn many multiples of its Chinese revenue potential.

The scale of the resulting flow is now unmistakable. Chinese drugmakers signed a record ~$136 billion in out-licensing deals in 2025 — roughly 2.6x the ~$51.9 billion of 2024, and close to a tenfold jump from 2021’s ~$14 billion — and China now accounts for roughly a third of global out-licensing deal value, up from about a fifth in 2023-2024 (BioPharma Dive, FierceBiotech, DealForma data). A Jefferies analysis found Chinese out-licensing deals rose about 11% even as collective value soared. This is not a handful of opportunistic deals; it is a structural reallocation of where the industry sources de-risked innovation. We map the buyer economics step by step in our guide to in-licensing biotech assets from China.

The reason the trade works as an arbitrage rather than a simple purchase is the structure. Upfronts stay modest relative to headline “biobucks,” so the buyer stages cash against de-risking; territory splits keep the politically and commercially awkward home market with the originator; and option-to-license mechanics let buyers pay a smaller sum for the right to take full rights after a defined data readout. Each of those features lowers the buyer’s entry cost and risk — which is exactly what makes the spread an arbitrage and not just a fair price.

The Trade in Practice: Worked Examples

The thesis is best understood through the deals that prove it. The table below sets representative China-sourced transactions against the arbitrage logic. Figures are drawn from company announcements and major deal trackers; biobucks are total potential value including contingent milestones, not cash paid.

The ivonescimab deal is the signature case. Summit licensed Akeso’s PD-1/VEGF bispecific in late 2022 for ~$500 million upfront and up to ~$5 billion total, taking the US, Canada, Europe, and Japan while Akeso retained China and the rest of the world. The asset then went on to beat Keytruda on progression-free survival in a head-to-head Chinese trial — a result that, had the molecule originated in a US lab, would plausibly have commanded a multi-billion-dollar upfront or an outright takeout. That gap between what Summit paid and what an equivalent Western asset would have cost is the China discount made concrete.

The ADC wave generalizes the same logic across a modality. Chinese originators now drive the large majority of global ADC licensing activity, and the Merck-Kelun structure — ~$175 million upfront for a seven-asset platform worth up to ~$9.3 billion — shows how little cash a buyer risks to option a deep pipeline. We go deeper on the modality economics in our PD-1/VEGF bispecific landscape and in our guide to the top Chinese biotech companies.

The Counter-Case: Is the Discount Closing?

The honest answer is yes — and a buyer who ignores this is underwriting last year’s thesis. The most-cited evidence is blunt: the average upfront for a China-sourced licensing deal rose roughly 230%, from about $52 million in 2022 to about $172 million in early 2026, about 22% above the 2025 average of $141 million, according to industry analyses reported by FierceBiotech. The same reporting quotes analysts declaring that China is “no longer the bargain basement” for biopharma licensing, and a BioSpace analysis titled the dynamic “no longer a bargain pool.” In a third-party reading, DealForma data shows China and Hong Kong companies now account for about half of large-pharma in-licensing deals with at least $50 million upfront — a sign that buyers compete for these assets rather than picking them up quietly.

Three forces are compressing the spread:

• Rising upfronts. As above, cash at signing has more than tripled in four years on the deals that get reported. The era of a best-in-class molecule for a token upfront is ending on the headline categories.
• More competitive processes. The best assets now run through advised, multi-bidder processes. Once a modality such as PD-1×VEGF is on every BD team’s slide, a bidding war replaces a quiet bilateral negotiation — and the discount is competed away.
• Quality and policy caveats that buyers now price in. The FDA’s sintilimab precedent and ongoing data integrity scrutiny (including FDA warning letters to Chinese testing labs) mean buyers fund confirmatory multiregional trials and deeper diligence — costs that narrow the net spread even when the headline upfront still looks low. The BIOSECURE Act adds a policy overlay covered in our out-licensing report.

But “closing” is not “closed,” and the closure is highly uneven. The discount has compressed most where competition has arrived — premium ADCs, PD-1/VEGF bispecifics, and now obesity peptides. It persists where competition has not: differentiated assets in less-crowded therapeutic areas, earlier clinical stages, and deals sourced through relationships before a process forms. The thesis is therefore evolving, not dying: the arbitrage is migrating from modality to timing and access. The edge now belongs to whoever can find and lock the asset before the auction exists.

What the Discount Is Really Paying For

A serious buyer treats part of the China discount not as profit to be captured but as compensation for risks that must be diligenced and, where real, funded. Conflating the two is how the arbitrage destroys value. Three risk buckets deserve explicit pricing:

• Regulatory translatability. The 2022 ODAC rejection of sintilimab — voted 14-1 that single-country Chinese data did not reflect US patient diversity — is the canonical warning. A pivotal package run entirely in China may require an expensive multiregional confirmatory trial before FDA or EMA approval. That cost belongs in the underwriting, not in the celebration.
• Data integrity and IP provenance. Sourcing an asset without a clean, ICH-compatible audit trail is the single greatest avoidable risk in China licensing. Inventorship, chain of title, and trial-site data quality demand more diligence than a comparable Western deal — the work, not the discount, is what protects the buyer.
• Political and structural durability. Deals must survive a harder geopolitical line: clean ex-China territory splits, supply and data arrangements that avoid restricted vendors, and terms that anticipate further designations under BIOSECURE-style rules.

What It Means for a Buyer’s Sourcing Strategy

Operationally, the thesis dictates a sourcing model, not just a willingness to look at Chinese deals. Four disciplines follow directly from everything above:

• Source before the auction. Because the discount now survives mainly on assets that have not yet attracted a competitive process, proximity and relationships in Greater China are decisive. By the time an asset reaches a Western banker’s teaser, the spread is usually gone. A competitive auction is evidence you are already late.
• Diligence the risk premium, not just the science. Build a China-specific diligence stack — data provenance, IP title, trial-site quality, and FDA/EMA translatability — and price the residual risk into the deal rather than assuming the discount covers it.
• Structure for contingency. Use option-to-license mechanics, staged milestones, clean territory splits, and cross-border tax and royalty design that reflect the political realities. Structure is where the buyer keeps the arbitrage alive even as headline upfronts rise.
• Move on differentiation and timing, not modality fashion. Chasing the headline class (today PD-1×VEGF) means paying the price-discovered, post-arbitrage price. Sourcing differentiated assets in less-contested areas early is where the remaining discount lives.

This is precisely the work of a cross-border advisor with senior teams on both sides of the Pacific. As one of the leading firms connecting the China and Western biotech markets — with senior teams in Hong Kong, Shanghai, Zurich, and Chicago and one of the deepest China-West deal networks — Vision Lifesciences sources assets before they reach a process, diligences the China-specific risk, and structures transactions that hold the arbitrage together as the market matures. Our in-licensing advisory and the team behind it are detailed on our about page.